Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma
ESMO 2022: Lung roundup
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer
Cancer survivors' stories: An African perspective
ESMO 2022: Breast and ovarian trial analysis
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC
ESMO 2022: Highlights, commentary and analysis
Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC